CO5611194A2 - Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales - Google Patents

Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales

Info

Publication number
CO5611194A2
CO5611194A2 CO04079404A CO04079404A CO5611194A2 CO 5611194 A2 CO5611194 A2 CO 5611194A2 CO 04079404 A CO04079404 A CO 04079404A CO 04079404 A CO04079404 A CO 04079404A CO 5611194 A2 CO5611194 A2 CO 5611194A2
Authority
CO
Colombia
Prior art keywords
carbon
substituents
substituent
antitumural
transferasa
Prior art date
Application number
CO04079404A
Other languages
English (en)
Spanish (es)
Inventor
Hugh Y Zhu
Bama Santhanam
F George Njoroge
Patrick A Pinto
Alan B Cooper
Bancha Vibulbhan
Kartik M Keertikar
Dinanath F Rane
Carmen S Alvarez
Keith P Minor
W Robert Bishop
Ronald J Doll
James J-S Wang
Vallabhan Girija
Jagdish Desai
John J Baldwim
Chia-Yu Huang
Ge Li
A James Ray
Original Assignee
Shcering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Shcering Corp, Pharmacopeia Drug Discovery filed Critical Shcering Corp
Publication of CO5611194A2 publication Critical patent/CO5611194A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO04079404A 2002-02-27 2004-08-13 Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales CO5611194A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
CO5611194A2 true CO5611194A2 (es) 2006-02-28

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04079404A CO5611194A2 (es) 2002-02-27 2004-08-13 Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales

Country Status (19)

Country Link
US (1) US7342016B2 (enExample)
EP (1) EP1492772A1 (enExample)
JP (1) JP2005525356A (enExample)
KR (1) KR20040098004A (enExample)
CN (1) CN100537542C (enExample)
AR (1) AR039557A1 (enExample)
AU (1) AU2003215389B2 (enExample)
BR (1) BR0308071A (enExample)
CA (1) CA2477328A1 (enExample)
CO (1) CO5611194A2 (enExample)
IL (1) IL163673A0 (enExample)
MX (1) MXPA04008303A (enExample)
NO (1) NO20044053L (enExample)
NZ (1) NZ534809A (enExample)
PE (1) PE20031038A1 (enExample)
PL (1) PL372335A1 (enExample)
RU (1) RU2004128465A (enExample)
TW (1) TW200303867A (enExample)
WO (1) WO2003072549A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20160203A1 (sr) 2003-05-30 2016-10-31 Genentech Inc Tretman sa anti-vegf antitelima
RU2006106768A (ru) * 2003-08-07 2007-09-20 Шеринг Корпорейшн (US) Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
JP2008501031A (ja) * 2004-05-28 2008-01-17 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
CA2591123A1 (en) * 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
US20060205755A1 (en) * 2004-12-21 2006-09-14 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
EP1973882A1 (en) * 2006-01-19 2008-10-01 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
WO2008054598A2 (en) * 2006-09-29 2008-05-08 Schering Corporation Panel of biomarkers for prediction of fti efficacy
KR20140148491A (ko) * 2006-12-19 2014-12-31 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegf-특이적 길항제
EP2313091A4 (en) * 2008-07-14 2012-04-04 Univ Kingston PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
CN115385892A (zh) * 2021-10-28 2022-11-25 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) * 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
AU8854091A (en) * 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
DE69635424T2 (de) * 1995-12-22 2006-08-03 Schering Corp. Zur hemming der g-protein-funktion und zur behandlung proliferativer krankheiten geeignete tricyclische amide
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CN1237176A (zh) * 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
KR20000036111A (ko) 1996-09-13 2000-06-26 둘락 노먼 씨. 파네실 단백질 트랜스페라제 억제제인 트리사이클릭 항종양성화합물
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
HUP0004627A2 (hu) 1997-06-17 2001-10-28 Schering Corp. Farnezil-protein transzferáz inhibitor hatású új triciklusos szulfonamidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
NZ501571A (en) 1997-06-17 2002-02-01 Schering Corp Novel n-substituted urea inhibitors of farnesyl-protein transferase
AU753863B2 (en) 1997-06-17 2002-10-31 Schering Corporation Benzo(5,6)cyclohepta(1,2-B)pyridine derivatives for the inhibition of farnesyl protein transferase
AU753658B2 (en) 1997-06-17 2002-10-24 Pharmacopeia, Inc. Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
TR200101755T2 (tr) 1998-12-18 2001-09-21 Schering Corporation Trisiklik farnezil protein transferaz inhibitörleri.
SK7582001A3 (en) 1998-12-18 2002-03-05 Schering Corp Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
EP1255537B1 (en) 2000-02-04 2006-04-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
RU2006106768A (ru) * 2003-08-07 2007-09-20 Шеринг Корпорейшн (US) Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты

Also Published As

Publication number Publication date
AU2003215389B2 (en) 2007-10-18
AU2003215389A1 (en) 2003-09-09
EP1492772A1 (en) 2005-01-05
CN100537542C (zh) 2009-09-09
TW200303867A (en) 2003-09-16
AR039557A1 (es) 2005-02-23
JP2005525356A (ja) 2005-08-25
BR0308071A (pt) 2004-12-21
KR20040098004A (ko) 2004-11-18
PE20031038A1 (es) 2004-01-10
US20040122018A1 (en) 2004-06-24
RU2004128465A (ru) 2005-09-27
MXPA04008303A (es) 2005-11-23
WO2003072549A1 (en) 2003-09-04
NZ534809A (en) 2007-12-21
CN1630641A (zh) 2005-06-22
US7342016B2 (en) 2008-03-11
IL163673A0 (en) 2005-12-18
CA2477328A1 (en) 2003-09-04
PL372335A1 (en) 2005-07-11
NO20044053L (no) 2004-11-26

Similar Documents

Publication Publication Date Title
CO5611194A2 (es) Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR080189A2 (es) Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de la replicacion del vhc
AR057688A1 (es) CARBOXAMIDAS HETEROCíCLICAS Y SU USO EN COMPOSICIONES FUNGICIDAS.
CO5640109A2 (es) Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen
BRPI0507617A (pt) antagonistas de receptor de quimiocina
AR057209A1 (es) Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas
RU2004132204A (ru) Имидазоконденсированные соединения
SE0202430D0 (sv) New Compounds
AR087051A2 (es) Una composicion inhibidora del virus de la hepatitis c y uso
AR048376A1 (es) C- glicosidos heterociclos fusionados sustituidos
MX346367B (es) Derivado de triazina y composicion farmaceutica que tiene actividad analgesica que comprende el mismo.
AR040475A1 (es) Espiropiperidinas o espiropirrolidinas triciclicas
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
ATE517874T1 (de) Pyrimidinone als modulatoren von caseinkinase ii (ck2)
AR046202A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
NO20071880L (no) Diagnostic Compounds
BRPI0507312A (pt) derivados de quinolina para uso como inibidores micobacterianos
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR046992A1 (es) Derivados de espiro-dihidrobenzofuranos
AR041855A1 (es) 4 amino-1- (piridilmetil) piperidina sustituida y compuestos relacionados
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed